Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01675882 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Several Doses of Viaskin Peanut in Adults and Children With Peanut Allergy
A Phase 2 study, sponsored by DBV Technologies.
- Completed
- Registry status
- Phase 2
- Development phase
- 221
- Enrollment target
NCT01675882 is a Phase 2 study that has completed, run by DBV Technologies. The registered enrollment target is 221 participants.
The verdict
NCT01675882, a Phase 2 study, has completed, sponsored by DBV Technologies.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 221 participants
- Enrollment target
Study Summary
The objectives of this dose-finding study for the treatment of peanut allergy are: * To determine the efficacy of 3 doses of Viaskin Peanut (50 mcg ,100 mcg and 250 mcg peanut protein per patch) to significantly desensitize peanut-allergic subjects to peanut after 12 months of treatment. * To evaluate the safety of a long-term treatment with Viaskin Peanut.
Interventions
- BIOLOGICAL Viaskin Peanut 250 mcg
- BIOLOGICAL Viaskin Placebo
- BIOLOGICAL Viaskin Peanut 50 mcg
- BIOLOGICAL Viaskin Peanut 100 mcg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 221 participants |
| Start Date | 2012-08 |
| Est. Completion | 2014-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01675882
The ClinicalTrials.gov registry entry for NCT01675882 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 221 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is DBV Technologies, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Viaskin Peanut 250 mcg is the first listed.
NCT01675882 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01675882 about?
NCT01675882 is a clinical study titled "Efficacy and Safety of Several Doses of Viaskin Peanut in Adults and Children With Peanut Allergy". The objectives of this dose-finding study for the treatment of peanut allergy are: * To determine the efficacy of 3 doses of Viaskin Peanut (50 mcg ,100 mcg and 250 mcg peanut protein per patch) to significantly desensitize peanut-allergic subjects to peanut after 12 months of treatment. * To evalu...
What is the current status of trial NCT01675882?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 221 participants. The study started on 2012-08. Estimated completion is 2014-07.
What interventions are being tested in trial NCT01675882?
The interventions under investigation include: Viaskin Peanut 250 mcg (BIOLOGICAL), Viaskin Placebo (BIOLOGICAL), Viaskin Peanut 50 mcg (BIOLOGICAL), Viaskin Peanut 100 mcg (BIOLOGICAL).
Who is sponsoring clinical trial NCT01675882?
This trial is sponsored by DBV Technologies, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.